European Urology

Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer

Abstract

Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.

The paper

Royal Marsden NHS Foundation Trust

European Urology, 15 Sep 2026

doi.org/10.1016/j.eururo.2026.07.025PubMed 42744693